跳到正文
原文
Endpoints News 生物医药· Elizabeth Cairns·· 2026-10-19AI 评分54

AbbVie称Skyrizi组合疗法在中期克罗恩病试验中优于单药

AbbVie’s Skyrizi combo beats Skyrizi alone in mid-stage Crohn’s trial

AI 导读

AbbVie于周一表示,以Skyrizi为基础、用于炎症性肠病的组合疗法在克罗恩病中期试验中效果优于Skyrizi单药。可读部分未披露具体疗效数据、组合中的另一药物及试验规模。

正文

Ab­b­Vie’s Skyrizi-based com­bi­na­tion ther­a­py for in­flam­ma­to­ry bow­el dis­ease worked bet­ter than Skyrizi alone in a mid-stage tri­al in Crohn’s dis­ease, the com­pa­ny said Mon­day.

The …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news